Glivec case final hearing in India rescheduled for Sept
This article was originally published in Scrip
Executive Summary
The Indian patent case concerning Novartis' anticancer, Glivec (imatinib mesylate), and its rejection due to a controversial provision in India's patent law, will now come up for hearing in the Supreme Court only in September.